Boshen Jiao
University of Washington
H-index: 11
North America-United States
Top articles of Boshen Jiao
Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana
Applied Health Economics and Health Policy
2024/1/24
Boshen Jiao
H-Index: 6
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
Value in Health
2024/1/6
Boshen Jiao
H-Index: 6
Anirban Basu
H-Index: 10
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015–2019
Value in Health
2024/4/23
Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis
Annals of Internal Medicine
2024/2
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
PharmacoEconomics
2023/12
Boshen Jiao
H-Index: 6
Gender Disparities in Blood Pressure and the Role of Body Mass Index: A Birth Cohort Analysis in China
Journal of Epidemiology and Global Health
2023/9
Jinjing Wu
H-Index: 3
Boshen Jiao
H-Index: 6
Associating health-related quality-of-life score with time uses to inform productivity measures in cost-effectiveness analysis
Pharmacoeconomics
2023/9
Boshen Jiao
H-Index: 6
Anirban Basu
H-Index: 10
Economic Evaluation of a Point-of-Care Test for Bacterial Vaginosis Among Women With Vaginal Symptoms
Sexually Transmitted Diseases
2023/5/1
Boshen Jiao
H-Index: 6
Sujatha Srinivasan
H-Index: 10
Value-based pricing for patent-protected medicines over the product life cycle: pricing anomalies in the “Age of Cures” and their implications for dynamic efficiency
Value in Health
2023/3/1
Boshen Jiao
H-Index: 6
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
Blood Advances
2023/2/14
Boshen Jiao
H-Index: 6
Anirban Basu
H-Index: 10
Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance–A retrospective cohort study
Plos one
2022/11/29
Does clinical evidence of heterogeneity impact treatment selection? A case study of abiraterone for metastatic prostate cancer
Journal of the National Comprehensive Cancer Network
2022/10/1
Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease
Quality of Life Research
2022/9
Boshen Jiao
H-Index: 6
Anirban Basu
H-Index: 10
A landscape analysis and discussion of value of gene therapies for sickle cell disease
2022/8/18
Boshen Jiao
H-Index: 6
Anirban Basu
H-Index: 10
Is the direct anterior approach to THA cost-effective? A Markov analysis
Clinical Orthopaedics and Related Research®
2022/8/1
Michael B Held
H-Index: 2
Boshen Jiao
H-Index: 6
HSD7 Does Clinical Evidence of Heterogeneity Influence Treatment Selection? a Case Study of Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer
Value in Health
2022/7/1
EE210 Value of Expanding First-Line Treatment Choices: New Metrics for Economic Evaluation
Value in Health
2022/7/1
Boshen Jiao
H-Index: 6
EE462 Value-Based Pricing for Patent-Protected Medicines: Pricing Anomalies in the" Age of Cures” and Their Implications for Dynamic Efficiency
Value in Health
2022/7/1
Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis
2022/7
Urbanization and systolic/diastolic blood pressure from a gender perspective: Separating longitudinal from cross-sectional association
Health & Place
2022/5/1
Jinjing Wu
H-Index: 3
Boshen Jiao
H-Index: 6
